Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

Oncology: Endocrine

  • You have access
    First-in-human study of novel SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety and efficacy
    Richard P. Baum, Jingjing Zhang, Christiane Schuchardt, Dirk Mueller and Helmut Maecke
    Journal of Nuclear Medicine March 5, 2021, jnumed.120.258889; DOI: https://doi.org/10.2967/jnumed.120.258889
  • You have access
    A Prospective Randomized, Double-blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors
    li huo, Wenjia Zhu, Yuejuan Cheng, Ru Jia, Hong Zhao, Chunmei Bai, Jianming Xu and Shaobo Yao
    Journal of Nuclear Medicine February 12, 2021, jnumed.120.253096; DOI: https://doi.org/10.2967/jnumed.120.253096
  • Open Access
    Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): The NETPET score as a prognostic biomarker
    David L Chan, Gary A Ulaner, David A. Pattison, David Wyld, Rahul Ladwa, Julian Kirchner, Bob T Li, W. Victoria Lai, Nick Pavlakis, PAUL J ROACH and Dale L. Bailey
    Journal of Nuclear Medicine February 12, 2021, jnumed.120.257659; DOI: https://doi.org/10.2967/jnumed.120.257659
  • You have access
    Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
    caroline bodet-milin, Alain faivre-chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, delphine Drui, David M Goldenberg, Robert M Sharkey, Jacques Barbet and Francoise Kraeber-Bodere
    Journal of Nuclear Medicine February 5, 2021, jnumed.120.252791; DOI: https://doi.org/10.2967/jnumed.120.252791
  • You have access
    Synthesis and evaluation of 18F-enzalutamide, a new radioligand for PET Imaging of Androgen Receptors: A comparison with 16β-18F-fluoro-5α-dihydrotestosterone
    Inês F. Antunes, Rutger Dost, Hilde D. Hoving, Aren van Waarde, Rudi A. Dierckx, Douwe F. Samplonius, Wijnand Helfrich, Philip H Elsinga, Erik F de Vries and Igle J. de Jong
    Journal of Nuclear Medicine January 30, 2021, jnumed.120.253641; DOI: https://doi.org/10.2967/jnumed.120.253641
  • You have access
    A rapid and safe infusion protocol for lutetium-177 peptide receptor radionuclide therapy
    Sander C. Ebbers, Maarten W. Barentsz, Bart de Keizer, Gerard C. Krijger, Marnix G.E.H. Lam and Arthur J.A.T. Braat
    Journal of Nuclear Medicine November 27, 2020, jnumed.120.252494; DOI: https://doi.org/10.2967/jnumed.120.252494
  • You have access
    Effects of Repeated 131I-meta-iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activities in Patients with Metastatic Neuroendocrine Tumors
    Keiichiro Yoshinaga, Takashige Abe, Shozo Okamoto, Yuko Uchiyama, Osamu Manabe, Yoichi M. Ito, Naomi Tamura, Natsue Ito, Naho Yoshioka, Komei Washino, Nobuo Shinohara, Nagara Tamaki and Tohru Shiga
    Journal of Nuclear Medicine October 16, 2020, jnumed.120.250803; DOI: https://doi.org/10.2967/jnumed.120.250803
  • You have access
    18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients
    Tina Binderup, Ulrich Knigge, Camilla Bardram Johnbeck, Annika Loft, Anne Kiil Berthelsen, Peter Oturai, Jann Mortensen, Birgitte Federspiel, Seppo W Langer and Andreas Kjaer
    Journal of Nuclear Medicine October 16, 2020, jnumed.120.244798; DOI: https://doi.org/10.2967/jnumed.120.244798
  • You have access
    First experience using F-18-flubrobenguane PET imaging in patients with the suspicion of pheochromocytoma or paraganglioma
    Lukas Kessler, Anna Melissa Schlitter, Markus Kroenke, Alexander von Werder, Robert Tauber, Tobias Maurer, Simon P Robinson, Cesare Orlandi, Michael Herz, Behrooz H Yousefi, Stephan G. Nekolla, Markus Schwaiger, Matthias Eiber and Christoph Rischpler
    Journal of Nuclear Medicine August 28, 2020, jnumed.120.248021; DOI: https://doi.org/10.2967/jnumed.120.248021
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire